The Wrong and Right Way to Go About Debt — Economy After COVID-19
We’ve handled the COVID-19 health risk pretty damn well. However, moving forward we will face the next challenge. That is, keeping our economy in tact without maxing out on debt…
We’ve handled the COVID-19 health risk pretty damn well. However, moving forward we will face the next challenge. That is, keeping our economy in tact without maxing out on debt…
Rare earths juggernaut Lynas Corporation Ltd [ASX:LYC] has raced out of the gate this morning. The Lynas share price is up 17% at time of writing. Surging on the back of confirmation that the US military will fund their plans for a Texas plant….
After prices for crude oil went negative yesterday (-US$37.63), markets were hoping for a reprieve. Indeed, some wrote off this unprecedented turn of events as simply a short-term anomaly…
ScoMo on Thursday afternoon. Articulating his vision for a ‘pro-growth’ agenda. It was easily the biggest takeaway from the PM’s speech. Because beyond the virus and all its immediate ramifications, long term the economy is the bigger quandary…
Ultimately, the answer to this question is going to come down to preference. As I mentioned, ETFs are great for investors who don’t want too much choice. That doesn’t mean there isn’t room for some choice though.
COVID-19 is testing us. Testing just how much liberty we’re willing to give up in the name of safety. My concern though, is how far are we willing to go?
There is an exodus in China. It dawned on producers that relying only on China is risky. If their supply chain is compromised — be it via a trade war or otherwise. Then the coronavirus (COVID-19) struck. An event that could be the nail in the coffin of China’s manufacturing supremacy…
Last Friday 3.28 million was the most important number. It was a new record for US unemployment claims. Dwarfing the previous high of 695,000 claims back in 1982. The first significant statistical indicator of just how bad this ‘corona’ recession will be…
While the ASX falters, one small-cap is booming. The share price of Rhythm Biosciences Ltd [ASX:RHY] is up 127% at time of writing. Surging on the back of an update in regards to the company’s cancer screening tech.
As we’re currently seeing, governments and central banks around the world are undertaking a giant experiment. In the words of our Prime Minister, they’re trying to ‘pause’ the economy. Pumping billions or even trillions of dollars into industries to survive the collapse in demand.
Investment ideas from the edge of the bell curve.
Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.
All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.
The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.
Fat Tail Daily is brought to you by the team at Fat Tail Investment Research
Copyright © 2026 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988